Traditional Chinese medicine (TCM) has made eminent contributions to human health in East Asia over the past thousand years, owning the advantages that their effectiveness testified directly on numerous individuals initially in ancient times. Recently, TCM has drawn increasing interest worldwide for its complementary and alternative therapies compared with Western medicine and its remarkable ability to address various difficult diseases[@b1][@b2][@b3]. Herbal formulas are developed from combinations of various herbs at appropriate doses guided by TCM theory. These formulas contain multiple ingredients and affect numerous targets[@b4]. Bioactive ingredients in herbal formulas are responsible for the therapeutic effects and are essential to improve quality standards[@b5][@b6]. However, the bioactive ingredients in most herbal formulas are unclear. Current quality control methods for herbal formulas in China rather than bioactivities are merely based on physical and chemical analyses[@b7]. To develop herbal formulas, it is urgently necessary to define and perform proper controls of the core bioactive ingredients.

The association between the TCM chemical characteristics and bioactive effects was first proposed in 2002[@b8]. Over the past decade, more and more meaningful trials aiming to connect TCM ingredients and bioactive effects have been published[@b9][@b10][@b11]. For example, a researcher in China discovered the core bioactive components effective against blood circulation disorders in a traditional Chinese herbal formula Compound Xueshuantong Capsule by analysing the association between the data of high-performance liquid chromatography (HPLC) characteristic peaks and bioactive effects[@b9]. These researches focused more on the bioactive ingredients than on single or multiple components with relatively high contents in herbs, and such explorations have provided valuable references for quality control, herb classification, TCM prescription optimization, new medicinal plant identification, and drug discovery[@b12][@b13].

Kouyanqing Granule (KYQG) is a traditional Chinese herbal formula composed of *Flos lonicerae* (FL, flower bud of *Lonicera macranthoides* Hand.-Mazz.), *Radix scrophulariae* (RS, root of *Scrophularia ningpoensis* Hemsl.), *Radix ophiopogonis* (RO, root of *Ophiopogon japonicus* (Thunb.) Ker-Gawl.), *Radix asparagi* (RA, root of *Asparagus cochinchinensis* (Lour.) Merr.), and *Radix et rhizoma glycyrrhizae* (RG, root of *Glycyrrhiza uralensis* Fisch.). KYQG is well known in China for its curative effects against inflammatory disorders of the mouth and throat, such as recurrent aphthous ulcers, traumatic ulcers, oral leukoplakia, and oral lichen planus[@b14][@b15]. The bioactive ingredients in KYQG that exert anti-inflammatory effects remain unknown. In contrast with the typical method of separating and then biologically testing the components individually, this study was designed to establish an approach using a relevance analysis between the chemical characters from UFLC-DAD-Q-TOF-MS/MS (Ultra-fast liquid chromatography-Diode array detector-Quadrupole-Time-of-flight-Tandem mass spectrometry) technology and *in vitro* anti-inflammatory effects, ultimately defining the core bioactive ingredients in KYQG.

Results
=======

Preparation of KYQG samples
---------------------------

Uniform design (UD), a method particularly suitable for multi-factor, multi-level experiments, was proposed by Fang and Wang based on the Quasi-Monte Carlo method or number-theoretic method[@b16]. UD has the significant merit of producing samples with high representativeness in the experimental domain. A five-factor, eleven-level UD was adopted to insure differences among the eleven KYQG samples ([Table 1](#t1){ref-type="table"}).

UFLC-DAD-Q-TOF-MS/MS analysis
-----------------------------

Thirty-eight ingredients were identified or tentatively characterized via UFLC-DAD-Q-TOF-MS/MS. Among the thirty-eight ingredients, twenty-five ingredients were confirmed by retention time and MS data of reference substances, and thirteen ingredients were characterized by MS data and related studies[@b17][@b18][@b19][@b20][@b21][@b22][@b23][@b24][@b25] ([Table 2](#t2){ref-type="table"}, [Fig. 1](#f1){ref-type="fig"}). Given the rescaled distance was 5, cluster analysis results revealed that eleven KYQG samples could be divided into eight classes as follows: S2 and S4 belonged to one class, S3 and S5 belonged to one class, S9 and S10 belonged to one class, and other samples comprised their own class ([Fig. 2](#f2){ref-type="fig"}).

Evaluation of *anti-inflammatory* activity *in vitro*
-----------------------------------------------------

### Cell viability assay

Cigarette smoke extract (CSE, 1-5%), dexamethasone (Dex, 1--100 μM), Niuhuangjiedu Pian (NP, 10-100 μg/mL), KYQG of original formula (S6, 2.2-555.6 μg/mL), and KYQG S1-S11 samples (55.6 μg/mL) exhibited no cytotoxic activity in 24-hour cultures ([Table 3](#t3){ref-type="table"}). ***Cytokine measurement by enzyme-linked immunosorbent assay (ELISA). Anti-inflammatory effects of KYQG S6:***The production of four pro-inflammatory cytokines increased significantly in the model group (*P* \< 0.05, *P* \< 0.01). After treatment, TNF-α, IL-8 and IL-1β levels decreased significantly in the Dex (1, 10 μM), NP (10 μg/mL), and KYQG S6 (5.6, 55.6, 555.6 μg/mL) groups (*P* \< 0.05, *P* \< 0.01). IL-6 levels decreased significantly in Dex (10 μM) and KYQG S6 (55.6, 555.6 μg/mL) groups (*P* \< 0.05) ([Table 4](#t4){ref-type="table"}, [Fig. 3](#f3){ref-type="fig"}). ***Anti-inflammatory effects of KYQG S1-S11 samples:*** The production of TNF-α, IL-8, IL-6, and IL-1β increased significantly in the model group (*P* \< 0.01). After treatment, Dex was significantly effective at reducing the levels of the four pro-inflammatory cytokines (*P* \< 0.05, *P* \< 0.01). NP significantly decreased TNF-α, IL-8, and IL-1β levels (*P* \< 0.01). For KYQG S1-S11 samples, the contents of TNF-α decreased significantly in the S1, S4, S5, S6, and S11 groups (*P* \< 0.05, *P* \< 0.01). IL-8 levels decreased significantly in the S5 and S6 groups (*P* \< 0.05, *P* \< 0.01). IL-6 levels decreased significantly in the KYQG samples with the exception of the S3 and S7 groups (*P* \< 0.05, *P* \< 0.01). IL-1β levels decreased significantly in the KYQG samples with the exception of the S1, S2, and S7 groups (*P* \< 0.05, *P* \< 0.01) ([Table 5](#t5){ref-type="table"}, [Fig. 4](#f4){ref-type="fig"}). These data indicate large differences in the anti-inflammatory parameters among the eleven KYQG samples.

Bioactive ingredients o**n** ***anti-inflammatory*** effects in KYQG
--------------------------------------------------------------------

Correlations among thirty-eight independent variables (identified ingredients) and four dependent variables (anti-inflammatory effects) were analysed to assess the contribution of each ingredient utilizing grey relational analysis (GRA), principal component analysis (PCA), and partial least-squares (PLS) methods ([Table 6](#t6){ref-type="table"}). ***Calculated results of IL-1β:*** Harpagide (P12), angoroside C (P23), harpagoside (P27), cinnamic acid (P28), and ruscogenin (P37) effectively contributed to the inhibition of IL-1β release. ***Calculated results of TNF-α:*** Chelidonic acid (P8), neochlorogenic acid (P13), chlorogenic acid (P14), cryptochlorogenic acid (P15), luteolin-7-O-glucoside (P19) and 3, 5-dicaffeoylquinic acid (P21) were the major ingredients effective at suppressing TNF-α release. ***Calculated results of IL-8:***L-pyroglutamic acid (P9), neochlorogenic acid (P13), cryptochlorogenic acid (P15), isoquercitrin (P18), and 3, 4-dicaffeoylquinic acid (P20) had the closest relevance to attenuating IL-8 release. ***Calculated results of IL-6:*** Lysine (P1), γ-aminobutyric acid (P6), tyrosine (P10), angoroside C (P23), and ruscogenin (P37) were more closely related to attenuating IL-6 release. In addition, a dynamic KYQG ingredient-effect relevance bubble chart and a dynamic KYQG herb-effect relevance bubble chart based on the computed results are provided as supplementary files (KYQG ingredient-effect relevance bubble chart S1, KYQG herb-effect relevance bubble chart S2) to illustrate a clear picture of the anti-inflammatory effects of the 38 identified ingredients and 5 herbs.

Discussion
==========

Oral mucosa keratinocytes comprise the main component of the oral mucosa epithelial cells, acting as a major barrier for oral diseases. After stimulation, oral mucosa keratinocytes produce cytokines that are involved in inflammatory processes. In addition, CSE contains a variety of harmful chemicals and causes inflammatory disorders in keratinocytes or epithelial cells, thus inducing the overexpression of pro-inflammatory cytokines, such as tumour necrosis factor-α (TNF-α), interleukin (IL)-1, IL-6, and IL-8[@b26][@b27][@b28]. Keratinocytes were treated with 5% CSE to generate an *in vitro* inflammation model in the present study.

Some recent evidence suggests that TNF-α, IL-8, IL-6, and IL-1β are notable mediators of inflammation, playing a prominent part in the development and progression of inflammatory disorders[@b29]. TNF-α induces the production of inflammatory mediators (e.g., IL-1, IL-6, etc.), promoting inflammatory cell migration. IL-8 possesses diverse functions, participating in the activation of neutrophils and the chemotaxis of neutrophils, T cells, and basophils. IL-6 regulates the proliferation, differentiation, and migration of inflammatory cells. IL-1β induces the expression of adhesion molecules and enhances leukocyte migration[@b30][@b31][@b32]. Recurrent aphthous ulcers, oral mucositis, oral lichen planus and other oral inflammatory disorders are generally associated with parasecretion of various pro-inflammatory cytokines (e.g., TNF-α, IL-1β, IL-6, IL-8, etc.)[@b33][@b34][@b35][@b36][@b37]. Thus, the modulation of pro-inflammatory cytokine production is conducive to recovery from oral inflammatory disorders. The KYQG S6 (original formula) results revealed that the alleviation of oral inflammatory disorders by the Chinese herbal formula KYQG is potentially related to the regulation of TNF-α, IL-8, IL-6, and IL-1β.

Mathematically, the relevance analysis of UFLC-DAD-Q-TOF-MS/MS characters and bioactive effects is an assessment of correlations between variables. Numerous mathematical statistical methodologies are available, and every method has its own theoretical basis and scope of application. Thus, the combination of several suitable methods is necessary to comprehensively and truly reflect the information from the experimental data. GRA's basic ideology is to estimate the associated degree of factors by studying the change in their similarity. The method is applicable to problems with complicated interrelationships among multiple factors and variables and is feasible in multiple attribute decision[@b38][@b39]. With the GRA method, the degree of association between each ingredient and bioactive effects is visually presented. However, multicollinearity problems can occur among the 38 original independent variables only using GRA. Thus, PCA and PLS were employed. PCA can reassemble the original variables into several mutually independent variables, and then some of the latter variables may be taken to reflect the original variables as much as possible[@b40]. In this study, five principal components were extracted from the original variables, contributing to 94.36% of the total variance. The scores between five principal components and the original variables were computed for their conversion ([Table 7](#t7){ref-type="table"}). PLS regression initiated by S. Wold and C. Albano is a novel multivariate statistical approach with the merits of overcoming the multicollinearity problem among the independent variables, discriminating between system signals and noises, and explaining dependent variables. Furthermore, the technique can integrate three analytical approaches: multiple linear regression, PCA, and typical correlation analysis. Overall, the combination of GRA, PLS, and PCA methods are helpful to reveal the relevance of ingredients and bioactive effects.

Organic acids and flavonoids are the main effective ingredients in FL[@b41]. Neochlorogenic acid (P13), chlorogenic acid (P14), cryptochlorogenic acid (P15), 3,4-dicaffeoylquinic acid (P20), and 3,5-dicaffeoylquinic acid (P21) are organic acids. Isoquercitrin (P18) and luteolin-7-O-glucoside (P19) are flavonoids. Neochlorogenic acid (P13) reportedly inhibits H~2~O~2~ and TNF-α-induced IL-8 secretion *in vitro*[@b42]. Chlorogenic acid (P14) attenuates the production of TNF-α[@b43], and 3,4-dicaffeoylquinic acid (P20) suppresses prostaglandin E~2~ release[@b44]. In addition, 3,5-dicaffeoylquinic acid (P21) inhibits TNF-α gene expression in lipopolysaccharide (LPS)-stimulated cells[@b45]. Isoquercitrin (P18) suppresses the release of macrophage inflammatory protein-2 and prostaglandin E~2~ *in vivo*[@b46], and luteolin-7-glucoside (P19) reduces LPS-induced TNF-α release from mouse macrophages[@b47]. Computed results in this study, which are consistent with these reports, demonstrate that the 5 organic acids and 2 flavonoids noted above are anti-inflammatory ingredients in KYQG.

Harpagide (P12), angoroside C (P23), harpagoside (P27), and cinnamic acid (P28) are the bioactive components in RS that exert anti-inflammatory activities as evidenced by numerous *in vivo* and *in vitro* reported experiments. Harpagoside (P27) prevents IL-1β production by RAW 264.7[@b48]. Harpagide (P12) possesses anti-inflammatory activity in carrageenan-induced inflammation *in vivo*[@b49]. Angoroside C (P23) exhibits activity in the regulation of nitric oxide (NO) in LPS-stimulated macrophages[@b50]. Cinnamic acid (P28) reduces LPS-stimulated IL-6 production in macrophages. These 4 ingredients exhibit a close relevance to anti-inflammatory effects and are also the active ingredients in KYQG.

Steroidal saponins are the main bioactive compounds in RO that perform anti-inflammatory, anti-aging, anti-tumour, and immunomodulatory activities. Ruscogenin (P37) is a steroidal saponin. Previous research has demonstrated that ruscogenin (P37) can inhibit LPS-induced lung inflammation by down-regulating intercellular adhesion molecule-1 and suppressing NF-κB activation in anti-inflammatory pathways[@b51][@b52]. The high levels of chelidonic acid (P8) in RA can reduce dextran sulphate sodium-induced TNF-α production[@b53]. Our results indicated that ruscogenin (P37) might have positively contribute to the inhibition of IL-1β and IL-6, and chelidonic acid (P8) potentially positively contribute to the suppression of TNF-α. Thus, ruscogenin (P37) and chelidonic acid (P8) are considered to be the anti-inflammatory ingredients in KYQG.

Amino acids, such as lysine (P1) and γ-aminobutyric acid (P6), potentially accelerate wound healing and enhance immune ability[@b54][@b55]. γ-aminobutyric acid (P6) reportedly suppresses IL-6 release[@b56], and tyrosine (P10) significantly decreases gelatine-induced inflammation[@b57]. Consistent with these literatures, the calculated results demonstrate that several amino acids, including lysine (P1), γ-aminobutyric acid (P6), and tyrosine (P10), positively contribute to the suppression of IL-6 or IL-8. These amino acids are the anti-inflammatory ingredients found in KYQG.

In addition, several saponins exerted negative effects on the following anti-inflammatory parameters: macranthoidin B (P29) and macranthoside A (P30) against IL-1β; saponin 2 (P26) against IL-8 and TNF-α; dipsacoside B (P31) against IL-6; and ruscogenin (P37) against IL-8). These saponins may exert activities other than the anti-inflammatory parameters detected in the present study, and the interaction among these saponins and other bioactive ingredients should also be investigated. However, the specific pharmacological mechanisms need further exploration and verification.

In summary, a novel approach to define the bioactive ingredients of the anti-inflammatory activities in KYQG was established based on a series of UFLC-DAD-Q-TOF-MS/MS analyses and *in vitro* pharmacological experiments. Our results suggested that one specific proinflammatory cytokine could be affected by two or more bioactive ingredients, and the same bioactive ingredient could positively influence two or more proinflammatory cytokines, reflecting the synergy among the ingredients in the traditional Chinese herbal formula. A conclusion could be drawn based on the relevance analysis of ingredients and effects that lysine (P1), γ-aminobutyric acid (P6), chelidonic acid (P8), tyrosine (P10), harpagide (P12), neochlorogenic acid (P13), chlorogenic acid (P14), cryptochlorogenic acid (P15), isoquercitrin (P18), luteolin-7-O-glucoside (P19), 3,4-dicaffeoylquinic acid (P20), 3,5-dicaffeoylquinic acid (P21), angoroside C (P23), harpagoside (P27), cinnamic acid (P28), and ruscogenin (P37) are the core anti-inflammatory bioactive ingredients in KYQG.

Methods
=======

Preparation of samples
----------------------

The KYQG samples were prepared using a five-factor, eleven-level uniform design, in which eleven KYQG samples were prepared by changing the contents of 5 herbs. Sample 6 (S6) was the original KYQG formula ratio. For each sample, the 5 herbs were decocted twice with water, and the liquids were mixed together and filtered. After concentrating the filtrate, ethanol was added. The mixture was stirred thoroughly and then stood for at least 12 hours. The supernatant was later filtered followed by the recovery of ethanol and evaporation of water. Bioactive *in vitro* experiments were conducted as follows: each KYQG sample was diluted with RPMI-1640 medium. KYQG sample 6 (S6, the original formula) was added to the cultures at final concentration of 5.6, 55.6, and 555.6 μg/mL, and the other KYQG samples were maintained at a concentration of 55.6 μg/mL. After being filtered through a 0.22-μm sterile membrane filter (Millipore, Bedford, MA, USA), the KYQG samples were stored at 4 °C until required. The 5 herbs (batch No: 140815) were provided by Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Co., Ltd. (Guangzhou, China).

Reagents
--------

Dex, psoralen (National Institute for the Control of Pharmaceutical and Biological Products, Beijing, China); NP (Beijing Tong-ren-tang Technology Development Co., Ltd., Beijing, China); cigarettes (China Tobacco Guangdong Industrial Co., Ltd., Guangzhou, China); RPMI-1640 medium, penicillin, streptomycin (Hyclone Laboratories, Logan, UT, USA); and foetal bovine serum (FBS) (Gibco, USA) were used in this study. ELISA kits for tumour necrosis factor-α (TNF-α), interleukin-8 (IL-8), interleukin-6 (IL-6), and interleukin-1β (IL-1β) (USCN Life Science, Wuhan, China) were employed. In addition, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) (Sigma, USA) was also utilized.

UFLC-DAD-Q-TOF-MS/MS analysis
-----------------------------

Analyses of the KYQG samples were performed using UFLC-DAD-Q-TOF-MS/MS, an ultra-fast liquid chromatography (Shimadzu, Japan) coupled with an SPD-M20A diode array detector (DAD; Shimadzu, Japan) and quadrupole/time-of-flight mass spectrometry (Triple TOF 5600 mass spectrometer, AB SCIEX, USA). Each KYQG sample was suspended in 10 mL of methanol/purified water (50:50, v/v) and filtered through a 0.22-μm membrane, with 100 μL psoralen \[52.24 μg/mL in methanol/purified water (50:50, v/v)\] added as an internal standard. Then, the sample was diluted with methanol/purified water (50:50, v/v) to a final concentration of 0.15 g/mL for analysis. Gradient chromatographic separation was performed on a Dionex Bonded Silica C~18~ column (3 μM, 150 mm × 4.6 mm) and operated at 40 °C. The injection volume was 5 μL, and the flow rate was 0.3 mL/min. The mobile phase consisted of acetonitrile containing 0.1% formic acid (A) and water containing 0.1% formic acid (B). The elution program was 0 to 7 min (98--90% B), 7 to 95 min (90--59% B), 95 to 105 min (59-0%B), and 105 to 115 min (0%B). The DAD scanned from 190 nm to 400 nm. Electrospray ionization (ESI) source was operated in the positive ion mode with the following settings: ion spray voltage  =  5500 V, source gas 1 = 55 psi, source gas 2 = 55 psi, ion source heater temperature = 550 °C, curtain gas setting = 35 psi, and collision gas pressure = 10 psi. Nitrogen was used as a nebulizer and auxiliary gas. The ingredients in KQYG were identified or tentatively characterized according to the mass spectrum data, related literature, and reference substances. To assess the difference among the prepared eleven KYQG samples, the relative peak areas of identified ingredients calibrated by psoralen (internal standard) were entered into SPSS 19.0 (SPSS, Inc., Chicago, IL, USA) to conduct a cluster analysis. Between-group linkage as the amalgamation rule was applied in this study, whereas Pearson's correlation was employed to calculate distance.

Evaluation ***of anti-inflammatory activi***ty *in vitro*
---------------------------------------------------------

### Cell cultures

Human oral keratinocytes (HOK, Guangzhou Jenniobio Biotechnology Company, Guangzhou, China), were cultured in RPMI-1640 medium supplemented with 10% foetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin. All cells were grown in a 37 °C incubator (5% CO~2~, 95% air) and passaged at approximately 90% confluence. All assays using HOK were performed within the 10th passage in 24- or 96-well plates. ***Preparation of cigarette smoke extract.***CSE was prepared as described previously[@b58][@b59][@b60] with the following modifications. Two cigarettes were combusted to produce 300 mL smoke, which was then sucked into a syringe containing 10 mL RPMI-1640 medium. After fully dissolved, the resulting suspension was filtered through a 0.22-μm filter, and this solution was defined as 100% CSE. Then, the desired concentrations of CSE (1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%) were obtained by further diluting 100% CSE with RPMI-1640 medium within 30 min. ***Cell Viability Assay.*** HOK (5 × 10^3^ cells/well) were cultured for 24 hours in 96-well plates and treated with various concentrations of CSE, Dex, NP, eleven KYQG samples for another 24 hours. Then, the MTT assay was conducted to assess the cell cytotoxicity. ***Cytokine measurement by ELISA.*** HOK (2 × 10^5^ cells/well) were cultured for 24 hours in 24-well plates and then serum-starved overnight. For experiments with KYQG S6 (the original formula), the cells were divided randomly into 8 groups as follows: control, model, Dex (1, 10 μM), NP (10 μg/mL), and KYQG S6 (5.6, 55.6, 555.6 μg/mL). For experiments with all the eleven samples, the cells were divided randomly into the following 15 groups: control, model, Dex (1 μM), NP (10 μg/mL), and KYQG S1-S11 samples (55.6 μg/mL). Different groups were pre-incubated with drugs or RPMI-1640 medium for 1 hour followed by an additional 24 hours with 5% of CSE (tested to exhibit no cytotoxic activity by MTT assay) or the same volume of RPMI-1640 medium. TNF-α, IL-8, IL-6 and IL-1β levels in the cell culture supernatants were determined with ELISA kits.

Mathematical methods of relevance analysis
------------------------------------------

### Data dimensionless

Relative peak areas of identified ingredients were regarded as independent variables ([Tables 8](#t8){ref-type="table"} and [9](#t9){ref-type="table"}), and values of anti-inflammatory effects were regarded as dependent variables ([Tables 10](#t10){ref-type="table"} and [11](#t11){ref-type="table"}). Negative effect values (the smaller the better) were converted to positive values by taking the reciprocal. All of the relative peak areas and effect values were then processed to be dimensionless by the equalization method for the relevance analysis. ***Grey relational analysis (GRA)***. GRA is a method of measuring the degree of influence between each given comparative series and the reference series in a system[@b61], and this degree of influence is referred to the grey relational degree (GRD). In this study, ingredient variables were taken as the comparative series, and the effect values (TNF-α, IL-8, IL-6 and IL-1β) were the reference series. GRD was calculated with a distinguishing coefficient of 0.5[@b61]. The higher the GRD, the greater the effect of corresponding ingredient. ***Principal component analysis (PCA)***. PCA is a popular technique for dimension reduction of multivariate problems[@b62]. All of the ingredient variables were simplified to a few new independent variables, which are mutual independent principal components. The regression equations between new principal components and effect values (TNF-α, IL-8, IL-6 and IL-1β) were established with a stepwise regression method. Once a regression equation was formed (*P* \< 0.05, IL-6 and IL-1β), the original independent variables would replace the new principal components to establish another proper multilinear regression equation. Regression coefficients (RCs) were used to estimating the effect contribution of each ingredient. When no available equations (*P* \> 0.05) were formed (IL-8 and TNF-α), Pearson's correlation coefficients (PCCs) between the original independent variables and effect values were computed directly. In the present study, the regression equation between extracted components and IL-1β was used, as follows: Y~IL-1β~ = 0.066 + 0.003 × Component4-0.001 × Component1 (*P* \< 0.05). After replacing the extracted components with the original variables, we obtain the following equation: Y~IL-1β~ = 0.066  + 3.51 × 10^−4^ P1 + 6.10 × 10^−4^ P2 + ......+ 7.91 × 10^−4^ P38. The regression equation between extracted components and IL-6 is noted as follows: Y~IL-6~ = 0.401 + 0.013 × Component4+0.008 × Component2 (*P* \< 0.05). After replacing the extracted components with the original variables, we obtain the following equation: Y~IL-6~ = 0.401 + 3.84 × 10^−3^ P1 + 4.15 × 10^−3^ P2+......+1.78 × 10^−3^ P38. ***Partial least-squares (PLS) regression***. PLS regression effectively settles the multicollinearity problem among variables and is suitable for situations in which the number of observations is less than the number of variables[@b63]. In this study, the standardized regression coefficients (RCs) in PLS regression between the independent variables and effect values (TNF-α, IL-8, IL-6 and IL-1β) were calculated to evaluate every ingredient's effect contribution. All of the processes above were implemented in SPSS 19.0.

Statistical analysis
--------------------

Data are presented as the mean ± standard deviation (S.D.) and processed by one-way analysis of variance (ANOVA), Student's t tests, and least significant difference multiple comparisons in SPSS 19.0. *P*-values less than 0.05 or 0.01 were considered to be statistically significant.
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![Chemical structural formula of the identified ingredients in KYQG (except for the conjectural saponin 1 and saponin 2[@b23]).](srep18080-f1){#f1}

![UFLC-Q-TOF-MS/MS characters (**A**) and cluster analysis results (**B**) of eleven KYQG samples. Twenty-five ingredients were confirmed by the retention time. The MS data of the reference substances and thirteen ingredients were characterized by MS data and related studies. Given the rescaled distance of 5, eleven KYQG samples could be divided into eight classes as follows: S2 and S4 belonged to one class, S3 and S5 belonged to one class, S9 and S10 belonged to one class, and the remainder of the samples constituted their own class.](srep18080-f2){#f2}

![The effects of KYQG (the original formula) on IL-1β, TNF-α, IL-8, and IL-6 production.\
Dex: Dexamethasone; NP: Niuhuangjiedu Pian; KYQG: Kouyanqing Granule. Groups: control group, model group, NP group (10 μg/mL), Dex groups (1 and 10 μM), and KYQG groups (5.6, 55.6, and 555.6 μg/mL). The control group and model group received the same volume of RPMI-1640 medium for the treatment. Each bar represents the contents of IL-1β, TNF-α, IL-8, and IL-6 as the mean ± SD, n = 3. ^\*^*P* \< 0.05 and ^\*\*^*P* \< 0.01 vs. control group, ^\#^*P* \< 0.05 and ^\#\#^*P* \< 0.01 vs. model group.](srep18080-f3){#f3}

![The effects of eleven KYQG samples on IL-1β, TNF-α, IL-8, and IL-6 production.\
Dex: Dexamethasone; NP: Niuhuangjiedu Pian; KYQG: Kouyanqing Granule. Groups: control group, model group, NP group (10 μg/mL), Dex group (1 μM), and eleven KYQG samples groups (55.6 μg/mL). Control group and model group received the same volume of RPMI-1640 medium for the treatment. Each bar represents the contents of IL-1β, TNF-α, IL-8, and IL-6 as the mean ± SD, n = 3. ^\*^*P* \< 0.05 and ^\*\*^*P* \< 0.01 vs. control group, ^\#^*P* \< 0.05 and ^\#\#^*P* \< 0.01 vs. model group.](srep18080-f4){#f4}

###### Weights and percentage of 5 herbs in the eleven KYQG samples under a uniform design.

         **FL (g-%)**   **RS (g-%)**   **RA (g-%)**   **RO (g-%)**   **RG (g-%)**
  ----- -------------- -------------- -------------- -------------- --------------
  S1      846.0−36.0        0−0         394.8−16.8     592.2−25.2     517.0−22.0
  S2      799.0−34.0      98.7−4.2      888.3−37.8      98.7−4.2      465.3−19.8
  S3      752.0−32.0     197.4−8.4      197.4−8.4      789.6−33.6     413.6−17.6
  S4      705.0−30.0     296.1−12.6     690.9−29.4     296.1−12.6     361.9−15.4
  S5      658.0−28.0     394.8−16.8        0−0         987.0−42.0     310.2−13.2
  S6      611.0−26.0     493.5−21.0     493.5−21.0     493.5−21.0     258.5−11.0
  S7      564.0−24.0     592.2−25.2     987.0−42.0        0−0         206.8−8.8
  S8      517.0−22.0     690.9−29.4     296.1−12.6     690.9−29.4     155.1−6.6
  S9      470.0−20.0     789.6−33.6     789.6−33.6     197.4−8.4      103.4−4.4
  S10     423.0−18.0     888.3−37.8      98.7−4.2      888.3−37.8      51.7−2.2
  S11     376.0−16.0     987.0−42.0     592.2−25.2     394.8−16.8        0−0

FL = Flos lonicerae; RS = Radix scrophulariae; RO = Radix ophiopogonis; RA = Radix asparagi; RG = Radix et rhizoma glycyrrhizae.

###### Identification details of the ingredients in KYQG represented by 38 peaks using a UFLC-Q-TOF-MS/MS technique.

  **Variables**     **Retention time (min)**   **Attribution^a^**        **Ingredients**         **Molecular formula**   **\[M + H\]**^**+**^   **\[M − H\]**^**−**^                                                                                                                **Positive mode**                                                                                                                                                                                      **Negative mode**
  ---------------- -------------------------- -------------------- ---------------------------- ----------------------- ---------------------- ---------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------
  P1                          4.92                     AL                   Lysine^b^              C~6~H~14~N~2~O~2~       147.1128 (−0.4)                                                                                                       130.0867\[M+H-NH~3~\]^+^, 84.0826\[M+H-NH~3~-HCOOH\]^+^, 67.0566\[M+H-2NH~3~-HCOOH\] ^+^                                                                                                                                                           
  P2                          5.27                     AL                  Arginine^b^             C~6~H~14~N~4~O~2~         175.1190 (0)          173.1058 (8.1)                                                               158.0934\[M+H-NH~3~\]^+^, 130.0985\[M+H-COOH\]^+^, 70.681\[M+H- NH~3~-C~3~H~6~NO~2~\]^+^, 60.0594\[M+H-C~5~H~10~NO~2~\]^+^                                                                                                               156.0767\[M-H-NH~3~\]^−^, 131.0827\[ M-H-C~3~H~6~\]^−^
  P3[@b17][@b19]              5.32                     AL                   Asparagine             C~4~H~8~N~2~O~3~        133.0606 (−1.4)                                                                                            116.0336\[M+H-NH~3~\]^+^, 87.0565\[M+H-HCOOH\]^+^, 74.0259\[M+H-C~2~H~5~NO\]^+^, 70.0312\[M+H-HCOOH-NH~3~\]^+^                                                                                                                                                
  P4                          5.36                     AL                Aspartic acid^b^            C~4~H~7~NO~4~          134.0451 (0.3)         132.0315 (1.2)                                                                                   116.0338\[M+H-H~2~O\]+, 88.0404\[M+H-HCOOH\]^+^, 74.0256\[M+H-NH~3~-CO-CH~3~\]^+^                                                                                                                      115.0045\[M-H-NH~3~\]^−^, 88.0413\[M-H-CO~2~\]^−^, 71.0154\[M-H- CO~2~-NH~3~\]^−^
  P5                          5.59                     AL                 Citrulline^b^            C~6~H~13~N~3~O~3~       176.1029 (−0.5)                                                                                                   159.0765\[M+H-NH~3~\]^+^, 113.0709\[M+H-NH~3~-HCOOH\]^+^, 70.0673\[M+H-NH~3~-CO~2~-CH~3~NO\]^+^                                                                                                                                                        
  P6[@b18]                    5.66                     AL              γ-aminobutyric acid           C~4~H~9~NO~2~         104.0706 (−0.1)                                                                                                           87.0457\[M+H-NH~3~\]^+^, 69.0359\[M+H-NH~3~-H~2~O\]^+^, 60.0835\[M+H-CO~2~\]^+^                                                                                                                                                                
  P7[@b19]                    6.05                     AL                    Proline                 C~5~H~9~NO~2~          116.0709 (0.8)                                                                                                                        70.0677\[M+H-HCOOH\]^+^, 68.0521\[M+H-HCOOH-H~2~O\]^+^                                                                                                                                                                            
  P8                          6.61                   RA/RO              Chelidonic acid^b^           C~7~H~4~O~6~           185.0082 (0.7)         182.9939 (1.8)                                                                                 141.0173\[M+H-CO~2~\]^+^, 97.0297\[M+H-2CO~2~\]^+^, 71.0152\[M+H-2CO~2~-C~2~H~2~\]^+^                                                                                                                   139.0038\[M-H-CO~2~\]^−^, 68.9988\[M-H-C~4~H~2~O~4~\]^−^, 67.0207\[M-H-2CO2-CO\]^−^
  P9[@b20]                   10.20                     AL               Pyroglutamic acid            C~5~H~7~NO~3~          130.0500 (1.1)                                                                                                                         84.0461\[M+H-HCOOH\]^+^, 56.0531\[M+H-HCOOH-CO\]^+^                                                                                                                                                                              
  P10                        11.13                     AL                  Tyrosine^b^              C~9~H~11~NO~3~         182.0811 (−0.2)                             165.0543\[M+H-NH~3~\]^+^, 147.0435\[M+H-NH~3~-H~2~O\]^+^, 136.0755\[\[M+H-HCOOH\]^+^, 119.0490\[\[M+H-HCOOH-NH~3~\]^+^, 91.0553\[M+H-HCOOH-NH~3~-CO\]^+^, 77.0403\[M+H-HCOOH-NH~3~-CO-CH~2~\]^+^, 65.04111\[M+H-HCOOH-NH~3~-CO-C~2~H~2~\]^+^                                                                                 
  P11                        15.28                     AL                Phenylalanine^b^           C~9~H~11~NO~2~          166.0864 (0.9)         164.0725 (4.6)                                                                                                120.0816\[M+H-HCOOH\]^+^, 103.0554\[M+H-HCOOH-NH~3~\]^+^                                                                                                                      165.0760\[M\], 147.0445\[M-H-NH~3~\]^−^, 103.0555\[M-H-NH~3~-CO~2~\]^−^, 72.0096\[M-H-NH~3~-C~6~H~5~\]^−^
  P12                        15.35                     RS                  Harpagide^b^             C~15~H~24~O~10~                               363.1282 (−1.2)                                                                                                                  387.1256\[M+Na\]^+^                                                                                                                409.1338\[M+COOH\]^−^, 201.0760\[M-H-Glc\]^−^, 183.0656\[M-H-Glc-H~2~O\]^−^, 165.0549\[M-H-Glc-H~2~O-H~2~O\]^−^, 139.0388\[M-H-Glc-H~2~O-H~2~O-C~2~H~2~\]^−^
  P13 [@b21]                 18.38                     FL              Neochlorogenic acid          C~16~H~18~O~9~         355.1025 (−1.9)        353.0877 (−0.8)                                             163.0396\[M+H- C~7~H~12~O~6~\]^+^, 145.0288\[M+H- C~7~H~12~O~6~-H2O \]^+^, 117.0342\[ M+H-C~7~H~12~O~6~-H2O-CO\]^+^, 89.0402\[M+H-C~7~H~12~O~6~-H2O-CO-CO\]^+^                                                                   191.0557\[M-H-C~9~H~6~O~3~\]^−^, 179.0344\[M-H-C~7~H~10~O~5~\]^−^, 135.0450\[M-H- C~7~H~10~O~5~-CO~2~\]^−^
  P14                        23.65                     FL              Chlorogenic acid^b^          C~16~H~18~O~9~          355.1026 (0.6)        353.0891 (−1.3)                                             163.0394\[M+H-C~7~H~12~O~6~\]^+^, 145.0290\[M+H-C~7~H~12~O~6~-H~2~O\]^+^, 117.0344\[M+H-C~7~H~12~O~6~-H~2~O-CO\]^+^, 89.0405\[M+H-C~7~H~12~O~6~-H~2~O-2CO\]^+^                                                                                                        191.0561\[M-H-C~9~H~6~O~3~\]^−^
  P15 [@b21]                 24.69                     FL             Cryptochlorogenic acid        C~16~H~18~O~9~          355.1027 (0.9)        353.0869 (−0.5)                                                                  163.0390\[M+H-C~7~H~12~O~6~\]^+^, 145.0284\[M+H-C~7~H~12~O~6~-H~2~O\]^+^, 117.0338\[M+H-C~7~H~12~O~6~-H~2~O-CO\]^+^                                                                 191.0548\[M-H-C~9~H~6~O~3~\]^−^, 173.0442\[M-H-C~9~H~6~O~3~-H~2~O\]^−^, 135.0441\[M-H-C~7~H~10~O~5~-CO~2~\]^−^, 93.0345\[M-H-C~9~H~7~O~4~-2H~2~O-COOH\]^−^
  P16                        28.59                     FL                Caffeic acid^b^             C~9~H~8~O~4~          181.0409 (−0.7)         179.0354 (0.2)                                                                                163.0387\[M+H-H~2~O\]^+^, 135.0439\[M+H-H~2~O-CO\]^+^, 89.3980\[M+H-H~2~O-CO-HCOOH\]^+^                                                                                                                                                135.0446\[M-H-CO~2~\]^−^
  P17                        42.04                     RG                 Liquiritin^b^             C~21~H~22~O~9~         419.1334 (−0.7)        417.1189 (−0.6)                                                                                               257.0803\[M+H-Glc\]^+^, 137.0224\[M+H-C~14~H~18~O~6~\]^+^                                                                                                                           255.0645\[M-H-Glc\]^−^, 135.0077\[M-H-C~14~H~18~O~6~\]^−^, 119.0489\[M-H-C~14~H~18~O~6~-Glc\]^−^
  P18                        42.69                     FL                Isoquercitrin^b^           C~21~H~20~O~12~        465.1027 (−0.1)        463.0876 (−1.3)                                                                                                                 303.0489\[M+H-Glc\]^+^                                                                                                                                     301.0351\[M-H-Glc\]-, 271.0240\[M-Glc-CHO\]^−^, 255.0285\[M-H-Glc-O-CHO\]^−^, 151.0016\[M-H-C~7~H~3~O~3~\]^−^
  P19                        43.44                     FL           Luteolin-7-O-glucoside^b^       C~21~H~20~O~11~        449.1077 (−0.3)        447.0917 (−2.3)                                                                                                                 287.0554\[M+H-Glc\]^+^                                                                                                                                                                                 285.0404\[M-H-Glc\]^−^
  P20 [@b22]                 46.33                     FL           3,4-Dicaffeoylquinic acid       C~25~H~24~O~12~        517.1335 (−1.0)        515.1178 (−1.3)                                                                           499.1231\[M+H-H~2~O\]^+^, 163.0389\[M+H-C~6~H~18~O~9~\]^+^, 145.0286\[M+H-C~6~H~18~O~9~-H~2~O\]^+^                                                                                                 353.0853\[M-H-C~9~H~6~O~3~\]^−^, 191.0541\[M-H-2C~9~H~6~O~3~\]^−^, 173.0435\[M-H-2C~9~H~6~O~3~-H~2~O\]^−^
  P21 [@b22]                 48.29                     FL           3,5-Dicaffeoylquinic acid       C~25~H~24~O~12~        517.1325 (−0.6)        515.1195 (−2.5)                                                                           499.1229\[M+H-H~2~O\]^+^, 163.0390\[M+H-C~6~H~18~O~9~\]^+^, 145.0280\[M+H-C~6~H~18~O~9~-H~2~O\]^+^                                                                                                 353.0867\[M-H-C~9~H~6~O~3~\]^−^, 191.0546\[M-H-2C~9~H~6~O~3~\]^−^, 173.0437\[M-H-2C~9~H~6~O~3~-H~2~O\]^−^
  P22 [@b22]                 52.11                     FL           4,5-Dicaffeoylquinic acid       C~25~H~24~O~12~         517.1336 (2.4)        515.1181 (−3.4)                                                                          499.1240\[M+H-H~2~O\]^+^, 163.0397\[M+H-C~16~H~18~O~9~\]^+^, 145.0289\[M+H-C~16~H~18~O~9~-H~2~O\]^+^                                                                                                353.0853\[M-H-C~9~H~6~O~3~\]^−^, 191.0541\[M-H-2C~9~H~6~O~3~\]^−^, 173.0435\[M-H-2C~9~H~6~O~3~-H~2~O\]^−^
  P23                        53.51                     RS                Angoroside C^b^            C~36~H~48~O~19~                                783.2723 (0.7)                                                                                                                  807.2675 \[M+Na\]^+^                                                                                                                                    607.2276\[M-H-C~6~H~11~O~4~-CHO\]^−^, 193.0492\[M-H-C~26~H~38~O~15~\]^−^, 175.0383\[M-H-C~26~H~38~O~15~-H~2~O\]^−^
  P24                        59.42                     RG              Isoliquiritoside^b^          C~21~H~22~O~9~         419.1334 (−0.7)        417.1177 (−0.6)                                                                                                257.0812\[M+H-Glc\]^+^, 137.0224\[M+H-Glc-C~8~H~6~O\]^+^                                                                                                                          255.0648\[M-H-Glc\]^−^, 119.0489\[M-H-Glc-C~8~H~6~O-H~2~O\]^−^, 92.0260\[M-H-Glc-C~9~H~7~O~3~\]^−^
  P25 [@b23]                 63.49                     RA                  Saponin 1^c^                   ---                 1035.5357                                                                                                                                        1035.5371, 579.3893,417.3358                                                                                                                                                                                         
  P26 [@b23]                 65.46                     RA                  Saponin 2^c^                   ---                  903.4940                                                                                                                                         903.4922,741.4405,417.3335                                                                                                                                                                                          
  P27                        70.83                     RS                 Harpagoside^b^            C~24~H~30~O~11~                               493.1679 (−4.9)                                                                                                                  517.1675\[M+Na\]^+^                                                                                                                                                                  539.1745\[M+COOH\]^−^, 147.0434\[M-H-C~15~H~22~O~9~\]^−^
  P28                        73.23                     RS                Cinnamic acid^b^            C~9~H~8~O~2~            149.0598 (0)          147.0452 (0.2)                                                                                                    131.0490\[M+H-H2O\]^+^, 103.0550\[M+H-HCOOH\]^+^                                                                                                                                                                    103.0529\[M-COOH\]^−^
  P29                        74.34                     FL               Macranthoidin B^b^         C~65~H~106~O~32~                               1397.6515 (−3.9)                                                                                                                 1421.6554\[M+Na\]^+^                                                                                                                                                                     1443.6582\[M+COOH\]^−^, 1073.5507\[M-H-2Glc\]^−^
  P30 [@b24]                 76.63                     FL                Macranthoside A            C~47~H~76~O~17~        913.5130 (−1.4)                                                                    782.4876\[M+H-H~2~O\]^+^, 751.4601\[M+H-Glc\]^+^, 455.3512\[M+H- Ara-Rha-Glc\]^+^, 437.3398\[M+H- Ara-Rha-Glc-H~2~O\]^+^, 409.3510\[M+H-Ara-Rha-Glc-HCOOH\]^+^                                                                                                                        
  P31                        79.46                     FL                Dipsacoside B^b^           C~53~H~86~O~22~                               1073.5561 (−2.1)                                                                                                                 1097.5470\[M+Na\]^+^                                                                                                                                                                     1119.5572\[M+COOH\]^−^, 749.4483\[M-H-2Glc\]^−^
  P32                        99.32                     RG              Glycyrrhetic acid^b^         C~30~H~46~O~4~                                469.3289 (−3.5)                                                                                                                  471.3460\[M+Na\]^+^                                                                                                                                                                                     469.3289\[M-H\]^−^
  P33                        99.33                     RG              Glycyrrhizic acid^b^         C~42~H~62~O~16~        823.4098 (−1.1)                                                                                                              471.3453\[M+H-2C~6~H~8~O~6~\]^+^, 453.3362\[M+H-2C~6~H~8~O~6~-H~2~O\]^+^,                                                                                                                                                                   
  P34 [@b25]                 105.34                    RG                  Gancaonin B              C~21~H~20~O~6~          369.1334 (0.3)                                                                                                 285.0765\[M+H-C~5~H~8~O\]^+^, 270.0525\[M+H-C~5~H~6~O~2~\]^+^, 255.0648\[M+H-C~5~H~6~O~2~-CH~3~\]^+^                                                                                                                                                     
  P35                        108.09                    RA               Sarsasapogenin ^b^          C~27~H~44~O~3~         417.3359 (−0.9)         415.3218 (3.9)                                                                                                         417.3353\[M+H\]^+^, 273.2216 225.2114                                                                                                                                                                                     
  P36                        108.92                    RO           Methylophiopogonanone A^b^      C~19~H~18~O~6~         343.1170 (−4.1)                                                                                                                  207.0644\[M+H-C~8~H~8~O~2~\]^+^, 135.0436\[M+H-C~11~H~12~O~4~\]^+^                                                                                                                                                                      
  P37                        109.09                    RO                 Ruscogenin^b^             C~27~H~4~2O~4~         431.3157 (−0.1)        429.3010 (−2.5)                                                                                                         431.3133\[M+H\]^+^, 287.2005, 269.1899                                                                                                                                                                                    
  P38                        109.09                    RO               Ophiopogonin D^b^           C~44~H~70~O~16~        855.4745 (−2.8)                                                                                                                               431.3172\[M-Man-Xyl-Gal-2O\]^+^ 287.2007                                                                                                                                                                                   

^a^FL = Flos lonicerae; RS = Radix scrophulariae; RO = Radix ophiopogonis; RA = Radix asparagi; RG = Radix et rhizoma glycyrrhizae; AL = 5 herbs.

^b^Identification compared with reference substances.

^c^Sarsasapogenin as aglycone.

^d^P3 [@b17][@b19], P6 [@b18], P7 [@b19], P9 [@b20], P13 [@b21], P15 [@b21], P20 [@b22], P21 [@b22], P22 [@b22], P25 [@b23], P26 [@b23], P30 [@b24], P34 ^25^ were characterized by MS data and related studies[@b17]−[@b25].

###### Cell viability.

       **Sample**          **CSE**                  **Dex**                                                                                                                                                                     
  -------------------- --------------- --------------------------------- ------------------ ---------------- ----------------- ------------------ ------------------ ------------------- ------------ ------------ ------------ ------------------
   Cell viability (%)    99.5 ± 2.5               96.1 ± 2.2                 95.4 ± 2.0        94.6 ± 3.6       90.8 ± 1.8      36.2 ± 2.1^\*\*^   18.5 ± 0.9^\*\*^    9.2 ± 0.4^\*\*^    99.7 ± 0.7   99.2 ± 1.8   93.5 ± 1.5   34.4 ± 0.7^\*\*^
       **Sample**          **NP**       **KYQG (the original formula)**                                                                                                                                                         
      **10 μg/mL**      **100 μg/mL**           **1000 μg/mL**             **2.2 μg/mL**     **22.2 μg/mL**   **222.2 μg/mL**   **555.6 μg/mL**    **2222.2 μg/mL**                                                             
   Cell viability (%)    91.9 ± 2.4               90.0 ± 1.2              10.5 ± 0.9^\*\*^     97.0 ± 3.1       95.6 ± 3.2         93.2 ± 3.0         90.7 ± 0.8      63.5 ±  0.9^\*\*^                                         
       **Sample**          **S1**                   **S2**                     **S3**            **S4**           **S5**             **S6**             **S7**             **S8**           **S9**      **S10**      **S11**    
   Cell viability (%)    91.2 ± 0.7               92.3 ± 1.3                 92.6 ± 2.7        90.8 ± 0.6       89.0 ± 2.3         90.3 ± 3.3         90.6 ± 1.9         89.0 ± 4.8       94.7 ± 0.6   91.4 ± 1.8   88.2 ± 1.8  

Data are shown as the mean ± SD, n = 3.

S1-S11 represented the eleven KYQG samples.

Cell viability in HOK after treatment with CSE, Dex, NP, KYQG (the original formula) and eleven KYQG samples (S1-S11) for 24 hours.

CSE: cigarette smoke extract; Dex: Dexamethasone; NP: Niuhuangjiedu Pian; KYQG: Kouyanqing Granule.

The cell viability of control group was defined as 100%. ^\*^*P* \< 0.05 and ^\*\*^*P* \< 0.01 vs. control group.

###### The effects of KYQG (the original formula) on IL-1β, TNF-α, IL-8, and IL-6 production.

   **Group**    **Dose**     **IL-1β (pg/mL)**    **TNF-α (pg/mL)**     **IL-8 (pg/mL)**     **IL-6 (pg/mL)**
  ----------- ------------- -------------------- ------------------- ---------------------- ------------------
    Control      Medium         13.12 ± 0.68         2.56 ± 0.25         463.67 ± 28.62        7.01 ± 0.22
     Model       Medium      27.23 ± 2.78^\*\*^    3.42 ± 0.36^\*^    745.62 ± 15.17^\*\*^   10.44 ± 0.94^\*^
      NP        10 μg/mL     16.59 ± 2.29^\#\#^   2.30 ± 0.26^\#\#^   517.02 ± 20.99^\#\#^     11.32 ± 1.40
      Dex         1 μM       18.14 ± 1.91^\#\#^   2.10 ± 0.23^\#\#^   555.48 ± 84.21^\#\#^     9.21 ± 0.50
      Dex         10 μM      15.51 ± 3.33^\#\#^   1.38 ± 0.04^\#\#^   555.34 ± 54.10^\#\#^   8.16 ± 0.45^\#^
     KYQG       5.6 μg/mL    19.22 ± 2.72^\#\#^   1.81 ± 0.27^\#\#^    607.59 ± 16.54^\#^      9.39 ± 0.78
     KYQG      55.6 μg/mL    18.62 ± 0.45^\#\#^   1.56 ± 0.26^\#\#^   551.73 ± 50.41^\#\#^   8.59 ± 0.57^\#^
     KYQG      555.6 μg/mL   9.65 ± 2.20^\#\#^    0.99 ± 0.26^\#\#^   521.55 ± 36.88^\#\#^   8.16 ± 0.25^\#^

Data are presented as the mean ± SD, n = 3.

Dex: Dexamethasone; NP: Niuhuangjiedu Pian; KYQG: Kouyanqing Granule.

Control group and model group received the same volume of RPMI-1640 medium for the treatment.

\**P* \< 0.05 and ^\*\*^*P* \< 0.01 vs. control group, ^\#^*P* \< 0.05 and ^\#\#^*P* \< 0.01 vs. model group.

###### The effects of eleven KYQG samples on IL-1β, TNF-α, IL-8, and IL-6 production.

   **Group**    **Dose**    **IL-1β (pg/mL)**    **TNF-α (pg/mL)**     **IL-8 (pg/mL)**     **IL-6 (pg/mL)**
  ----------- ------------ -------------------- ------------------- ---------------------- -------------------
    Control      Medium        11.63 ± 0.93         1.20 ± 0.02         215.11 ± 9.52          2.14 ± 0.05
     Model       Medium     20.28 ± 2.12^\*\*^   1.74 ± 0.03^\*\*^   272.93 ± 12.80^\*\*^   3.14 ± 0.11^\*\*^
      NP        10 μg/mL    10.64 ± 0.91^\#\#^   1.23 ± 0.09^\#\#^   239.81 ± 14.04^\#\#^      2.76 ± 0.16
      Dex         1 μM      15.21 ± 1.15^\#\#^   1.37 ± 0.02^\#\#^   230.85 ± 3.72^\#\#^     2.60 ± 0.27^\#^
      S1       55.6 μg/mL      18.92 ± 0.35      1.15 ± 0.10^\#\#^      289.76 ± 3.37       2.37 ± 0.14^\#\#^
      S2       55.6 μg/mL      18.06 ± 2.73         1.64 ± 0.19         265.53 ± 13.31      2.53 ± 0.19^\#\#^
      S3       55.6 μg/mL   15.83 ± 1.21^\#\#^      1.58 ± 0.12         261.08 ± 14.86         2.87 ± 0.34
      S4       55.6 μg/mL   14.72 ± 1.57^\#\#^   1.22 ± 0.07^\#\#^      341.33 ± 14.79      2.53 ± 0.16^\#\#^
      S5       55.6 μg/mL   15.96 ± 0.87^\#\#^    1.50 ± 0.12^\#^     250.25 ± 6.24^\#^      2.64 ± 0.19^\#^
      S6       55.6 μg/mL   12.62 ± 1.15^\#\#^   1.12 ± 0.14^\#\#^   237.00 ± 10.85^\#\#^   2.53 ± 0.16^\#\#^
      S7       55.6 μg/mL      17.44 ± 0.93         1.93 ± 0.11         252.69 ± 9.45          2.79 ± 0.30
      S8       55.6 μg/mL   13.11 ± 1.40^\#\#^      1.77 ± 0.02         341.92 ± 7.89       2.14 ± 0.14^\#\#^
      S9       55.6 μg/mL   14.23 ± 1.15^\#\#^      1.77 ± 0.08         288.33 ± 8.85       2.56 ± 0.14^\#\#^
      S10      55.6 μg/mL   14.35 ± 1.39^\#\#^      1.89 ± 0.11         259.30 ± 2.87        2.60 ± 0.22^\#^
      S11      55.6 μg/mL   13.61 ± 1.32^\#\#^   1.40 ± 0.15^\#\#^      279.84 ± 15.76      2.11 ± 0.14^\#\#^

Data are presented as the mean ± SD, n = 3.

S1-S11 represented the eleven KYQG samples.

Dex: Dexamethasone; NP: Niuhuangjiedu Pian; KYQG: Kouyanqing Granule.

Control group and model group received the same volume of RPMI-1640 medium for the treatment.

\*P \< 0.05 and \*\*P \< 0.01 vs. control group, ^\#^*P* \< 0.05 and ^\#\#^*P* \< 0.01 vs. model group.

###### Calculated results of the relevance between 38 ingredients and 4 effect parameters.

   **Ingredients**   **IL-1β**   **TNF-α**   **IL-8**           **IL-6**                                                      
  ----------------- ----------- ----------- ---------- ------- ---------- -------- ------- -------- -------- ------- -------- --------
         P1            0.703       3.512      −0.002    0.726    0.303     0.010    0.649   −0.278   −0.002   0.734   3.843    0.134
         P2            0.710       6.102      0.044     0.729    0.342     0.015    0.669   −0.256   0.009    0.733   4.154    0.057
         P3            0.716      −3.302      −0.109    0.750    0.300     −0.026   0.692   −0.263   −0.135   0.733   0.045    0.154
         P4            0.690      −3.064      −0.005    0.744    0.522     0.030    0.713   −0.184   −0.165   0.701   −0.384   0.059
         P5            0.625      −4.917      −0.214    0.617    −0.125    −0.092   0.596   0.072    0.485    0.626   0.892    −0.117
         P6            0.718       3.057      −0.051    0.742    0.377     0.028    0.663   −0.218   0.069    0.729   3.059    0.098
         P7            0.661      −0.825      −0.038    0.726    0.551     0.042    0.664   −0.160   −0.158   0.667   0.126    0.093
         P8            0.830      −1.948      0.002     0.890    0.654     0.104    0.835   −0.115   −0.415   0.860   0.727    0.287
         P9            0.805       1.358      −0.277    0.845    0.395     0.010    0.845   0.131    0.243    0.830   0.611    0.113
         P10           0.771       4.040      0.098     0.798    0.572     0.067    0.733   −0.170   −0.180   0.785   3.997    0.138
         P11           0.763       2.553      0.027     0.781    0.499     0.030    0.732   −0.172   −0.072   0.782   2.999    0.098
         P12           0.716       4.295      0.164     0.693    −0.253    −0.039   0.705   −0.224   0.039    0.751   4.582    0.066
         P13           0.797       4.204      −0.016    0.843    0.680     0.087    0.813   0.240    0.161    0.804   2.687    0.005
         P14           0.797       1.909      0.088     0.865    0.683     0.089    0.817   0.237    0.033    0.802   1.170    −0.009
         P15           0.797       3.016      0.015     0.851    0.649     0.079    0.813   0.276    0.158    0.802   1.988    −0.033
         P16           0.786       2.051      −0.037    0.792    0.434     0.003    0.773   −0.050   0.136    0.782   2.885    0.010
         P17           0.664      −3.325      0.028     0.736    0.526     0.021    0.691   0.043    −0.084   0.659   −1.445   −0.035
         P18           0.737       0.453      0.046     0.811    0.580     0.038    0.755   0.104    0.106    0.735   1.107    −0.058
         P19           0.772      −0.179      0.075     0.855    0.662     0.073    0.795   0.186    0.005    0.774   0.268    −0.017
         P20           0.809       2.948      −0.022    0.858    0.590     0.054    0.822   0.233    0.220    0.817   2.285    −0.053
         P21           0.798       1.100      0.116     0.870    0.703     0.084    0.802   0.081    −0.150   0.800   0.956    0.051
         P22           0.811       0.277      0.028     0.873    0.620     0.055    0.823   0.170    0.037    0.813   0.684    −0.011
         P23           0.799       7.737      0.271     0.724    −0.263    0.021    0.726   −0.243   −0.308   0.773   4.621    0.098
         P24           0.663      −3.070      0.062     0.718    0.620     0.059    0.634   0.038    −0.186   0.655   −1.741   0.010
         P25           0.635      −4.924      0.030     0.645    0.109     −0.015   0.613   −0.167   −0.221   0.638   0.707    0.151
         P26           0.646      −4.169      −0.107    0.619    −0.513    −0.141   0.604   −0.345   −0.356   0.642   0.497    0.134
         P27           0.788       7.508      0.169     0.746    −0.254    0.003    0.734   −0.057   −0.013   0.768   4.759    −0.022
         P28           0.707       4.293      0.073     0.645    −0.434    0.010    0.638   −0.017   −0.102   0.706   1.693    0.099
         P29           0.756      −8.238      −0.094    0.832    0.120     −0.084   0.781   −0.233   −0.044   0.779   −2.866   −0.136
         P30           0.816      −8.395      −0.138    0.859    −0.115    −0.124   0.848   −0.317   0.057    0.845   −2.066   −0.184
         P31           0.840      −8.689      −0.068    0.861    −0.129    −0.111   0.872   −0.411   −0.177   0.874   −3.022   −0.151
         P32           0.664      −3.409      0.068     0.727    0.546     0.033    0.677   0.006    −0.161   0.660   −1.698   −0.073
         P33           0.648      −6.697      0.010     0.711    0.340     −0.031   0.675   −0.095   −0.142   0.670   −2.782   −0.124
         P34           0.678      −4.975      −0.014    0.745    0.531     0.030    0.680   0.111    −0.035   0.672   −2.554   −0.038
         P35           0.690      −7.085      −0.040    0.673    −0.038    −0.011   0.646   0.083    0.066    0.663   −0.950   0.016
         P36           0.740      10.915      0.020     0.722    −0.055    0.060    0.743   0.082    −0.031   0.720   2.529    0.081
         P37           0.714       8.958      0.254     0.647    −0.268    0.003    0.657   −0.453   −0.624   0.683   3.595    0.378
         P38           0.666       7.906      −0.036    0.718    −0.002    0.068    0.683   0.082    0.186    0.680   1.779    0.002

For the results of grey relational degree (GRD), Pearson\'s correlation coeffiecient (PCC), and regression coefficient (RC), positive or negative values represent positive or negative effect contributions, respectively. The larger the absolute value, the higher the positive or negative effect contribution.

P12, P23, P27, P28, and P37 mainly contributed to IL-1β; P8, P13, P14, P15, P19, and P21 to TNF-α; P9, P13, P15, P18, and P20 to IL-8; P1, P6, P10, P23, and P37 to IL-6.

P29 and P30 might have a negative effect on IL-1β; P26 on TNF-α; P26 and P37 on IL-8; P31 on IL-6.

Lysine (P1), γ-aminobutyric acid (P6), chelidonic acid (P8), tyrosine (P10), harpagide (P12), neochlorogenic acid (P13), chlorogenic acid (P14), cryptochlorogenic acid (P15), isoquercitrin (P18), luteolin-7-O-glucoside (P19), 3,4-dicaffeoylquinic acid (P20), 3,5-dicaffeoylquinic acid (P21), angoroside C (P23), harpagoside (P27), cinnamic acid (P28) and ruscogenin (P37) are the core bioactive ingredients on anti-inflammatory effects.

The regression equation between the extracted components and IL-1β (stepwise regression): YIL-1β = 0.066 + 0.003 × Component4-0.001 × Component1 (P \< 0.05). After replacing the extracted components with the original variables: YIL-1β = 0.066 + 3.51 × 10^−4^P1 + 6.10 × 10^−4^P2+......+7.91 × 10^−4^P38.

The regression equation between extracted components and IL-6 (stepwise regression): YIL-6 = 0.401 + 0.013 × Component4 + 0.008 × Component2 (P \< 0.05). After replacing the extracted components with the original variables: YIL-6 = 0.401 + 3.84 × 10^−3^P1 + 4.15 × 10^−3^P2+......+1.78 × 10^−3^P38.

A dynamic KYQG ingredient-effect relevance bubble chart and a dynamic KYQG herb-effect relevance bubble chart based on the computed results are provided as the Supplementary File (KYQG ingredient-effect relevance bubble chart S1, KYQG herb-effect relevance bubble chart S2) to illustrate a clear picture of anti-inflammatory effects of the 38 identified ingredients and 5 herbs.

###### The scores of 5 principal components (extracted from 38 ingredient variables).

                 **P1**    **P2**    **P3**    **P4**    **P5**    **P6**    **P7**    **P8**    **P9**    **P10**   **P11**   **P12**   **P13**   **P14**   **P15**   **P16**   **P17**   **P18**   **P19**
  ------------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- ---------
   Component 1   0.1345    0.1400    0.1781    0.2027    0.0751    0.1437    0.1966    0.1654    0.1580    0.1768    0.1907    −0.0509   0.1846    0.1807    0.1789    0.1942    0.2029    0.2070    0.1942
   Component 2   0.2173    0.1129    0.0881    0.0082    0.3371    0.1390    −0.0461   0.1068    −0.0828   0.1851    0.1333    0.3677    0.0082    −0.0550   −0.0118   0.1443    −0.1105   0.0016    −0.0620
   Component 3   0.2265    0.2561    0.1993    0.1502    −0.0672   0.2704    0.1807    −0.0691   0.0815    0.0219    0.0992    −0.0019   −0.1664   −0.2337   −0.2217   0.0343    −0.0591   −0.0925   −0.1912
   Component 4   0.1619    0.2501    −0.0507   −0.0346   −0.1389   0.1498    0.0380    −0.0098   0.0980    0.1936    0.1487    0.1262    0.2017    0.1239    0.1602    0.1331    −0.0432   0.0841    0.0588
   Component 5   −0.0756   0.1121    −0.1443   −0.0791   −0.1173   −0.1469   −0.1104   −0.4302   −0.3572   0.0122    0.0330    0.1052    −0.0461   0.0626    0.0130    0.0643    0.1278    0.1460    0.0591
                   P20       P21       P22       P23       P24       P25       P26       P27       P28       P29       P30       P31       P32       P33       P34       P35       P36       P37       P38
   Component 1   0.1874    0.1994    0.1988    −0.1393   0.1964    0.0827    −0.0359   −0.1147   −0.2064   0.1722    0.1256    0.1014    0.1974    0.1927    0.1933    0.0085    −0.1167   −0.1250   −0.0940
   Component 2   0.0245    −0.0481   −0.0371   0.2340    −0.1578   0.3102    0.3074    0.2503    0.0909    −0.0053   0.1284    0.0379    −0.1345   −0.0893   −0.1545   0.2605    −0.2120   0.0318    −0.1549
   Component 3   −0.1669   −0.1488   −0.1717   −0.0358   −0.0486   −0.1278   −0.0525   −0.1178   −0.0711   0.2036    0.2689    0.3238    −0.0334   0.0339    −0.0758   −0.2542   0.1078    0.1760    0.2303
   Component 4   0.1608    0.1031    0.0755    0.2115    −0.0369   −0.1366   −0.1510   0.2120    0.0743    −0.2172   −0.2380   −0.2558   −0.0478   −0.1590   −0.1014   −0.2333   0.3250    0.2570    0.2322
   Component 5   0.0313    0.0669    0.0487    0.2555    0.0235    −0.1512   0.1147    0.3042    −0.0678   0.1503    0.1816    0.2094    0.1634    0.2468    0.0070    −0.2746   0.0330    0.0113    −0.2451

The 5 principal components contributed to 94.36% of the total variance.

The scores are for the conversion between 5 principal components and 38 ingredient variables.

###### Relative peak areas of 38 identified ingredients in the eleven KYQG samples.

         **P1**    **P2**    **P3**    **P4**    **P5**    **P6**    **P7**    **P8**    **P9**    **P10**   **P11**   **P12**   **P13**   **P14**   **P15**   **P16**   **P17**   **P18**   **P19**
  ----- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- ---------
   S1    0.0083    0.2467    0.0502    0.0287    0.0390    0.0193    0.9459    0.0615    1.1893    0.0967    0.1904    0.0000    1.0254    5.7467    1.2295    0.0492    0.1995    0.4112    0.3902
   S2    0.0086    0.1784    0.0525    0.0236    0.1198    0.0164    0.6218    0.0497    0.8337    0.0837    0.1763    0.0137    0.7539    5.0650    0.9823    0.0460    0.1803    0.4002    0.3564
   S3    0.0050    0.2052    0.0232    0.0187    0.0232    0.0117    0.5363    0.0378    0.7682    0.0578    0.1174    0.0100    0.7289    4.7275    0.9818    0.0348    0.1492    0.3405    0.3161
   S4    0.0066    0.1673    0.0351    0.0222    0.0589    0.0131    0.5501    0.0484    0.4935    0.0879    0.1550    0.0117    0.6923    4.9273    0.9296    0.0365    0.1630    0.3623    0.3399
   S5    0.0076    0.2456    0.0322    0.0167    0.0246    0.0170    0.5240    0.0342    0.7331    0.0679    0.1475    0.0091    0.6592    4.1273    0.8103    0.0375    0.1136    0.3136    0.2672
   S6    0.0032    0.1126    0.0118    0.0108    0.0378    0.0060    0.2897    0.0471    0.7259    0.0820    0.1261    0.0119    1.0891    6.9542    1.4232    0.0383    0.1602    0.4319    0.4384
   S7    0.0052    0.1213    0.0263    0.0136    0.1624    0.0089    0.2815    0.0469    0.6969    0.0760    0.1285    0.0189    0.8278    4.9017    1.0951    0.0430    0.1190    0.3424    0.3175
   S8    0.0079    0.2525    0.0289    0.0115    0.0451    0.0130    0.3428    0.0362    0.6906    0.0817    0.1521    0.0242    0.6589    4.0349    0.8430    0.0410    0.0869    0.2855    0.2454
   S9    0.0000    0.0040    0.0058    0.0027    0.0045    0.0011    0.0097    0.0363    0.5569    0.0045    0.0037    0.0128    0.3114    2.8818    0.5021    0.0048    0.0248    0.0893    0.1738
   S10   0.0001    0.0060    0.0042    0.0013    0.0041    0.0019    0.0147    0.0287    0.5091    0.0042    0.1904    0.0000    1.0254    5.7467    1.2295    0.0492    0.1995    0.4112    0.3902
   S11   0.0101    0.2246    0.0271    0.0129    0.1243    0.0189    0.3085    0.0494    0.6390    0.0907    0.1763    0.0137    0.7539    5.0650    0.9823    0.0460    0.1803    0.4002    0.3564
         **P20**   **P21**   **P22**   **P23**   **P24**   **P25**   **P26**   **P27**   **P28**   **P29**   **P30**   **P31**   **P32**   **P33**   **P34**   **P35**   **P36**   **P37**   **P38**
   S1    1.3639    1.2320    2.8844    0.0000    1.7443    0.0474    0.0233    0.0000    0.0000    0.0371    0.0194    0.0469    0.8648    1.6664    1.6664    0.4191    0.0213    0.0187    0.0304
   S2    1.1094    1.0761    2.5344    0.0167    1.3082    0.1186    0.0391    0.0908    0.0090    0.0344    0.0194    0.0449    0.6080    1.4686    1.4339    0.8219    0.0053    0.0134    0.0078
   S3    1.1265    0.9833    2.3728    0.0296    1.2500    0.0101    0.0006    0.1319    0.0146    0.0363    0.0201    0.0499    0.7493    1.5654    1.1853    0.2669    0.0226    0.0273    0.0370
   S4    1.0150    1.0787    2.3476    0.0503    1.2951    0.0986    0.0339    0.2230    0.0199    0.0340    0.0199    0.0489    0.7201    1.6315    1.2060    0.6666    0.0108    0.0112    0.0127
   S5    0.9453    0.8553    2.0386    0.0418    0.7775    0.0000    0.0000    0.2224    0.0248    0.0292    0.0186    0.0441    0.4329    1.0328    0.8605    0.0000    0.0315    0.0156    0.0279
   S6    1.4563    1.2943    2.9924    0.0510    1.2646    0.0589    0.0066    0.2955    0.0341    0.0174    0.0111    0.0294    0.6245    0.8991    1.2477    0.7304    0.0258    0.0156    0.0158
   S7    1.2508    0.9442    2.4701    0.0481    0.7081    0.1154    0.1234    0.3085    0.0302    0.0322    0.0207    0.0456    0.4881    1.2657    0.9057    1.2909    0.0000    0.0000    0.0000
   S8    1.0078    0.8650    2.0646    0.0795    0.4711    0.0504    0.1005    0.3660    0.0430    0.0266    0.0177    0.0431    0.3274    0.8295    0.4560    0.2247    0.0310    0.0550    0.0196
   S9    0.5557    0.5582    1.4838    0.0510    0.2562    0.0215    0.0578    0.2065    0.0634    0.0197    0.0143    0.0377    0.0987    0.2975    0.4634    0.8944    0.0184    0.0361    0.0178
   S10   1.3639    0.4979    1.2969    0.0536    0.1293    0.0143    0.0259    0.2469    0.0639    0.0172    0.0132    0.0383    0.0603    0.1763    0.2004    0.2248    0.0479    0.0324    0.0501
   S11   1.1094    0.6736    1.6604    0.0846    0.0000    0.1053    0.0627    0.3806    0.0601    0.0210    0.0173    0.0407    0.0000    0.0000    0.0000    1.0439    0.0193    0.0385    0.0387

S1-S11 represented the eleven KYQG samples.

P1-P38 represented 38 identified ingredients in KYQG and were regarded as the independent ingredient variables.

###### Dimensionless data of the 38 relative peak areas in the eleven KYQG samples.

         **P1**    **P2**    **P3**    **P4**    **P5**    **P6**    **P7**    **P8**    **P9**    **P10**   **P11**   **P12**   **P13**   **P14**   **P15**   **P16**   **P17**   **P18**   **P19**
  ----- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- ---------
   S1    1.4622    1.5383    1.8585    1.9385    0.6657    1.6695    2.3513    1.4201    1.6695    1.4514    1.5582    0.0000    1.4559    1.2845    1.3398    1.4604    1.8137    1.3947    1.3507
   S2    1.5144    1.1124    1.9402    1.5950    2.0476    1.4198    1.5457    1.1486    1.1703    1.2555    1.4425    1.0117    1.0703    1.1322    1.0704    1.3633    1.6388    1.3573    1.2335
   S3    0.8742    1.2796    0.8594    1.2632    0.3968    1.0122    1.3332    0.8730    1.0783    0.8669    0.9605    0.7359    1.0349    1.0567    1.0699    1.0308    1.3564    1.1547    1.0939
   S4    1.1642    1.0434    1.2967    1.5031    1.0070    1.1326    1.3675    1.1195    0.6927    1.3185    1.2682    0.8637    0.9829    1.1014    1.0130    1.0828    1.4818    1.2288    1.1763
   S5    1.3425    1.5313    1.1915    1.1265    0.4202    1.4700    1.3025    0.7895    1.0291    1.0191    1.2072    0.6726    0.9359    0.9226    0.8830    1.1124    1.0324    1.0637    0.9248
   S6    0.5610    0.7018    0.4383    0.7311    0.6464    0.5215    0.7202    1.0877    1.0189    1.2303    1.0321    0.8808    1.5462    1.5544    1.5509    1.1356    1.4565    1.4647    1.5175
   S7    0.9056    0.7563    0.9744    0.9179    2.7759    0.7667    0.6998    1.0832    0.9783    1.1408    1.0518    1.3969    1.1753    1.0956    1.1934    1.2750    1.0820    1.1611    1.0988
   S8    1.3803    1.5740    1.0674    0.7787    0.7701    1.1242    0.8521    0.8365    0.9694    1.2253    1.2444    1.7915    0.9355    0.9019    0.9187    1.2149    0.7899    0.9684    0.8494
   S9    0.0052    0.0251    0.2148    0.1822    0.0764    0.0921    0.0240    0.8379    0.7817    0.0682    0.0299    0.9494    0.4422    0.6441    0.5472    0.1414    0.2252    0.3028    0.6014
   S10   0.0092    0.0374    0.1560    0.0893    0.0696    0.1606    0.0366    0.6631    0.7146    0.0629    0.0427    0.3502    0.5145    0.5798    0.5839    0.1038    0.1233    0.2462    0.5025
   S11   1.7811    1.4004    1.0028    0.8743    2.1243    1.6308    0.7670    1.1409    0.8971    1.3612    1.1625    2.3473    0.9064    0.7268    0.8298    1.0797    0.0000    0.6576    0.6512
         **P20**   **P21**   **P22**   **P23**   **P24**   **P25**   **P26**   **P27**   **P28**   **P29**   **P30**   **P31**   **P32**   **P33**   **P34**   **P35**   **P36**   **P37**   **P38**
   S1    1.3225    1.3473    1.3140    0.0000    2.0845    0.8143    0.5403    0.0000    0.0000    1.3379    1.1120    1.0993    1.9124    1.6921    1.9044    0.7002    1.0008    0.7806    1.2959
   S2    1.0757    1.1769    1.1546    0.3633    1.5634    2.0370    0.9088    0.4039    0.2724    1.2386    1.1129    1.0511    1.3445    1.4913    1.6387    1.3732    0.2472    0.5571    0.3327
   S3    1.0923    1.0753    1.0810    0.6426    1.4939    0.1730    0.0142    0.5869    0.4422    1.3088    1.1534    1.1689    1.6570    1.5896    1.3546    0.4460    1.0630    1.1377    1.5776
   S4    0.9842    1.1796    1.0695    1.0932    1.5478    1.6941    0.7867    0.9923    0.6036    1.2272    1.1425    1.1457    1.5926    1.6567    1.3783    1.1138    0.5101    0.4656    0.5431
   S5    0.9166    0.9354    0.9287    0.9086    0.9292    0.0000    0.0000    0.9898    0.7513    1.0531    1.0675    1.0330    0.9573    1.0488    0.9834    0.0000    1.4793    0.6527    1.1918
   S6    1.4121    1.4155    1.3632    1.1078    1.5113    1.0113    0.1528    1.3149    1.0345    0.6263    0.6347    0.6877    1.3811    0.9130    1.4259    1.2203    1.2127    0.6514    0.6736
   S7    1.2128    1.0326    1.1253    1.0446    0.8462    1.9813    2.8657    1.3727    0.9155    1.1596    1.1860    1.0693    1.0793    1.2853    1.0350    2.1568    0.0000    0.0000    0.0000
   S8    0.9772    0.9460    0.9406    1.7274    0.5630    0.8648    2.3324    1.6284    1.3018    0.9601    1.0175    1.0107    0.7240    0.8423    0.5211    0.3755    1.4571    2.2937    0.8344
   S9    0.5388    0.6104    0.6760    1.1082    0.3062    0.3698    1.3430    0.9190    1.9226    0.7092    0.8224    0.8837    0.2184    0.3021    0.5296    1.4944    0.8665    1.5048    0.7610
   S10   0.5779    0.5445    0.5908    1.1647    0.1546    0.2464    0.6012    1.0985    1.9364    0.6215    0.7595    0.8969    0.1334    0.1790    0.2290    0.3756    2.2544    1.3498    2.1375
   S11   0.8899    0.7366    0.7564    1.8396    0.0000    1.8081    1.4549    1.6936    1.8197    0.7576    0.9916    0.9538    0.0000    0.0000    0.0000    1.7442    0.9090    1.6067    1.6525

S1-S11 represented the eleven KYQG samples.

P1-P38 represent 38 identified ingredients in KYQG and were regarded as the independent ingredient variables. P1-P38 were processed to be dimensionless by the equalization method for the calculation.

###### Switching of the effect parameters from negative to positive.

         **IL-1β**   **TNF-α**   **IL-8**   **IL-6**
  ----- ----------- ----------- ---------- ----------
   S1     0.0528      0.8706      0.0035     0.4214
   S2     0.0554      0.6100      0.0038     0.3959
   S3     0.0632      0.6317      0.0038     0.3484
   S4     0.0679      0.8206      0.0029     0.3959
   S5     0.0627      0.6671      0.0040     0.3787
   S6     0.0793      0.8923      0.0042     0.3959
   S7     0.0573      0.5171      0.0040     0.3580
   S8     0.0763      0.5664      0.0029     0.4665
   S9     0.0703      0.5664      0.0035     0.3900
   S10    0.0697      0.5286      0.0039     0.3843
   S11    0.0735      0.7139      0.0036     0.4749

S1-S11 represented the eleven KYQG samples.

Negative effect values (the smaller the better) were converted to positive values by taking the reciprocal.

###### Dimensionless data of the effect parameters after switching from negative to positive.

         **IL-1β**   **TNF-α**   **IL-8**   **IL-6**
  ----- ----------- ----------- ---------- ----------
   S1     0.7981      1.2968      0.9497     1.0511
   S2     0.8364      0.9087      1.0364     0.9875
   S3     0.9539      0.9409      1.0540     0.8692
   S4     1.0260      1.2223      0.8062     0.9875
   S5     0.9465      0.9937      1.0997     0.9446
   S6     1.1969      1.3292      1.1611     0.9875
   S7     0.8660      0.7702      1.0890     0.8929
   S8     1.1518      0.8437      0.8048     1.1636
   S9     1.0617      0.8437      0.9544     0.9728
   S10    1.0526      0.7874      1.0612     0.9585
   S11    1.1099      1.0633      0.9834     1.1847

S1-S11 represented the eleven KYQG samples.

Effect values of switched parameters were processed to be dimensionless by an equalization method for the calculation.

[^1]: These authors contributed equally to this work.
